EVERO Drug-coated Balloon (DCB) Randomized Trial
Eligible age
18+ yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
Sponsor: Cook Research Incorporated
You may qualify if…
- ✓ 1. Documented PAD with Rutherford classification 2 - 4; and
- ✓ 2. De novo or restenotic (non-stented) target lesion located in the native superficial femoral artery (SFA), popliteal artery (P1 or P2), or both native SFA and popliteal arteries.
You may not qualify if…
- ✕ General Exclusion Criteria
- ✕ 1. Less than 18 years old;
- ✕ 2. Inability or refusal to give informed consent by the patient or legally authorized representative;
- ✕ 3. Life expectancy ≤ 12 months, per investigator assessment;
- ✕ 4. Pregnant (or if absence of pregnancy is not verified by negative pregnancy test within 7 days of planned procedure), lactating, planning to become pregnant within 12 months of the planned procedure, or unwilling to use contraception for 12 months following the planned procedure;
- ✕ 5. Unable or unwilling to comply with the follow-up schedule; or
- ✕ 6. Simultaneously participating in another investigational drug or device study unless the patient is at least 30 days beyond the primary endpoint of any previous study.
Where it's recruiting
Long Beach
Danbury · New Haven
Washington D.C.
Gainesville · Jacksonville · Miami
Atlanta
Indianapolis
Davenport
Bay City
Tupelo
Lebanon
Camden
Philadelphia
Source: ClinicalTrials.gov · NCT07144150 · last updated 2026-11-20